February 28, 2015 9:00 AM ET

Pharmaceuticals

Company Overview of Agensys, Inc.

Company Overview

Agensys, Inc. engages in research and developing therapeutic fully human monoclonal antibodies (MAbs) to treat cancer. It develops products that include naked and antibody-drug conjugated (ADC) therapeutic antibodies to treat cancer indications, including prostate, kidney, pancreas, ovary, bladder, lung, colon, breast, and skin. The company develops AGS-1C4D4 for the treatment of pancreatic cancer; and various ADCs, such as AGS-16M8F, ASG-5ME, and ASG-22ME for treatment of various solid tumors. Agensys, Inc. was formerly known as UroGenesys, Inc. and changed its name to Agensys, Inc. in June 2001. The company was founded in 1996 and is based in Santa Monica, California. As of December 18, 20...

1800 Stewart Street

Santa Monica, CA 90404

United States

Founded in 1996

Phone:

310-820-8029

Fax:

310-820-8489

Key Executives for Agensys, Inc.

Chief Medical Officer and Senior Vice President
Age: 52
Executive Vice President, Chief Financial Officer and Vice President of Operations
Age: 68
Corporate Secretary and Corporate Counsel
Age: 64
Vice President of Business Development
Age: 55
Vice President of Clinical Research and Development
Compensation as of Fiscal Year 2014.

Agensys, Inc. Key Developments

Seattle Genetics and Agensys Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration

Seattle Genetics Inc. and Agensys, Inc. that Seattle Genetics has exercised an option to co-develop an additional antibody-drug conjugate (ADC) under the companies' existing ADC collaboration agreement. The ADC, called ASG-15ME, targets the tumor antigen SLITRK6, which is known to be expressed on bladder and lung cancer. Agensys has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 1 trial of ASG-15ME. ASG-15ME is an ADC composed of a fully human antibody directed to SLITRK6, an antigen expressed in multiple solid tumors. Preclinically, ASG-15ME has demonstrated antitumor activity in models of bladder and lung cancer. The antibody is attached to a potent, synthetic cytotoxic agent, monomethyl auristatin E (MMAE), via an enzyme-cleavable linker using Seattle Genetics' proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into SLITRK6-expressing tumor cells, resulting in targeted cell-killing. Upon the option exercise, Seattle Genetics will make an option exercise payment and thereafter fund half of the future development costs for the ASG-15ME program. The impact of the option exercise on Astellas' current fiscal year (from April 1, 2013, to March 31, 2014) financial forecast will be immaterial.

Similar Private Companies By Industry

Company Name Region
Decade Pharmaceuticals, LLC United States
Xenacare Holdings Inc. United States
Pharm Ops, Inc. United States
Research Services Inc. United States
Metagenics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Agensys, Inc., please visit www.agensys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.